• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Editor's Choice

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

February 11, 2026 Microbiome Times

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. […]

Editor's Choice

Immunity as a Lifestyle Priority

January 30, 2026 Romane Maillet

Immune health has evolved from a seasonal concern to an essential part of everyday well-being. Consumers are adopting proactive strategies that combine healthy lifestyle habits with advanced biotic solutions, driving innovation across the supplement industry. […]

Pharma & Human Health

‘GABA Factory’ Probiotic LP815® Improves Sleep and Reduces Stress

January 22, 2026 Microbiome Times

Verb Biotics U.S. Consumer Health Survey of 2,000 adults reported that 73% of consumers experience symptoms related to mental health, including stress and poor sleep. Among these, 40% said their symptoms affect daily functioning, highlighting […]

Pharma & Human Health

EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS

January 8, 2026 Microbiome Times

EnteroBiotix, a clinical-stage biopharmaceutical company focused on developing best-in-class therapies for gut health, today announced positive final results from TrIuMPH, a Phase 2a clinical trial evaluating EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic, in patients […]

Pharma & Human Health

AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244

December 9, 2025 Microbiome Times

AOB Pharma, Inc. (“AOBiome”), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions with their lead asset B244 for the treatment of mild to moderate atopic dermatitis (AD) and pruritus, received a positive decision […]

Pharma & Human Health

UC San Diego researchers develop new tool to predict how bacteria influence health

November 28, 2025 Microbiome Times

University of California San Diego researchers have developed an innovative new tool called coralME to better understand how microbes interact with each other and their environment to influence health. The tool rapidly creates detailed genome-scale […]

Pharma & Human Health

Traces of bacteria inside brain tumors may affect tumor behavior

November 24, 2025 Microbiome Times

Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets the […]

Pharma & Human Health

Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select

November 19, 2025 Microbiome Times

Delivering live biotherapeutics orally remains one of the challenges in microbiome therapy. In this white paper, Evonik presents a real-world case study of how EUDRACAP® Select—a ready-to-fill enteric capsule—enabled the safe and targeted delivery of […]

Editor's Choice

Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study

November 17, 2025 Microbiome Times

Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]

Editor's Choice

The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies

November 12, 2025 Heloise Breton, PhD

The women’s health gap refers to disparities in health outcomes and the limited research into conditions that exclusively affect women or affect them differently from men. This gap stems from the historic exclusion of females […]

Pharma & Human Health

Ferring Presents New Data Analyses for REBYOTA®

November 4, 2025 Microbiome Times

Ferring Pharmaceuticals shared an oral presentation last month detailing microbiome restoration from the Phase 3b CDI-SCOPE study among patients with recurrent C. difficile (C. diff) infection (CDI) who received REBYOTA® (fecal microbiota, live – jslm). This research was […]

Posts navigation

1 2 … 85 »

Download the MT Forum Agenda:

Sign Up to Free Newsletter

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
  • Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
    November 17, 2025
  • The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies
    November 12, 2025
  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
sign up

Sign up to the Microbiome Times newsletter